IMDX Insight Molecular Diagnostics Inc.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1642380 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY520.9%
TTM net income YoY-40.9%
TTM EPS YoY27.5%
Revenue 3-yr CAGR1.0%
Net income 3-yr CAGR—
Margins
Gross margin54.5%
Operating margin-1,392.9%
Net margin-1,380.7%
FCF margin-540.3%
EBITDA margin-1,343.0%
Returns
ROE-23,603.1%
ROA-106.5%
ROIC (approx.)—
Asset turnover0.08x
Leverage & solvency
Liabilities / assets120.9%
Debt / equity—
Current ratio2.79x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-68.2%
Payout ratio—
Capex / revenue43.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $559,000 | $239,000 | $32,000 | $1.14M | $260,000 | $518,000 | $2.14M | $1.49M |
| Cost of revenue | $139,000 | $82,000 | $17,000 | $643,000 | $121,000 | $180,000 | $813,000 | $869,000 |
| Gross profit | $420,000 | $157,000 | $15,000 | $496,000 | $139,000 | $338,000 | $1.32M | $595,000 |
| R&D expense | $3.79M | $4.49M | $4.95M | $5.83M | $3.88M | $3.27M | $2.92M | $2.26M |
| SG&A expense | $2.79M | $2.87M | $2.99M | $2.33M | $2.54M | $2.65M | $3.12M | $2.56M |
| Operating income | -$3.68M | -$11.40M | -$4.41M | -$23.43M | -$11.05M | -$9.84M | -$6.80M | -$33.63M |
| Pretax income | — | — | — | — | — | — | — | -$33.51M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$3.58M | -$11.26M | -$4.29M | -$22.95M | -$10.85M | -$9.74M | -$6.67M | -$33.51M |
| EBITDA | -$3.03M | -$10.74M | -$3.78M | -$22.87M | -$10.46M | -$9.28M | -$6.31M | -$33.06M |
| EPS (basic) | -0.10 | -0.31 | -0.12 | — | -0.34 | -0.30 | -0.26 | — |
| EPS (diluted) | -0.10 | -0.31 | -0.12 | — | -0.34 | -0.30 | -0.26 | — |
| Weighted avg. shares (diluted) | 36.86M | 36.75M | 34.52M | — | 32.03M | 32.02M | 25.69M | — |
| Banking | ||||||||
| Net interest income | -$17,000 | -$20,000 | -$23,000 | -$26,000 | -$29,000 | -$25,000 | -$29,000 | -$30,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $11.02M | $17.76M | $28.20M | $11.58M | $18.69M | $24.29M | $31.03M | $8.64M |
| Receivables | $520,000 | $192,000 | $157,000 | $1.13M | $258,000 | $512,000 | $3.54M | $1.61M |
| Inventory | $372,000 | $207,000 | $382,000 | $446,000 | $471,000 | $693,000 | $459,000 | $410,000 |
| Current assets | $13.88M | $20.54M | $30.52M | $15.31M | $21.39M | $26.84M | $36.26M | $11.76M |
| PP&E, net | $5.55M | $6.00M | $8.91M | $6.43M | $5.80M | $6.41M | $6.79M | $6.32M |
| Intangibles | — | — | — | $0 | $14.60M | $14.60M | $14.60M | $14.61M |
| Total assets | $21.74M | $29.44M | $40.43M | $25.76M | $43.94M | $50.52M | $60.36M | $35.08M |
| Current liabilities | $9.51M | $10.29M | $12.01M | $12.07M | $7.66M | $6.65M | $9.68M | $7.28M |
| Total liabilities | $45.92M | $50.74M | $51.12M | $57.22M | $53.13M | $49.42M | $50.14M | $47.35M |
| Shareholders' equity | -$24.18M | -$21.30M | -$10.69M | -$31.46M | -$9.20M | $1.10M | $10.22M | -$12.27M |
| Shares outstanding | 32.76M | 32.62M | 32.29M | 28.68M | 28.63M | 28.62M | 28.60M | 17.45M |
| Cash flow statement | ||||||||
| Operating cash flow | -$6.43M | -$9.27M | -$7.64M | -$5.54M | -$4.50M | -$6.17M | -$5.84M | -$5.35M |
| Capital expenditure | $841,000 | $779,000 | $613,000 | $1.48M | $1.05M | $349,000 | $307,000 | $214,000 |
| Free cash flow | -$7.27M | -$10.05M | -$8.25M | -$7.02M | -$5.55M | -$6.52M | -$6.15M | -$5.57M |
| Investing cash flow | -$841,000 | -$779,000 | -$613,000 | -$1.48M | -$1.05M | -$349,000 | -$307,000 | -$210,000 |
| Financing cash flow | $370,000 | -$564,000 | $24.70M | -$252,000 | -$120,000 | -$114,000 | $28.56M | $10.84M |
| Depreciation & amortization | $642,000 | $665,000 | $631,000 | $563,000 | $584,000 | $559,000 | $491,000 | $563,000 |
| Stock-based compensation | $820,000 | $661,000 | $615,000 | $721,000 | $521,000 | $504,000 | $473,000 | $499,000 |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.